MCRB Projected Dividend Yield
Seres Therapeutics Inc ( NASDAQ : MCRB )Seres Therapeutics is a microbiome therapeutics platform company developing live biotherapeutic drugs. SER-109, Co.'s lead clinical candidate is an oral, purified bacterial spore-based microbiome therapeutic candidate consisting of a consortium of purified Firmicutes spores. Using Co.'s microbiome therapeutics platform, Co. is also developing SER-287 and SER-301 to treat ulcerative colitis. Co. evaluates microbiome pharmacokinetic and pharmacodynamic data from across its clinical and pre-clinical portfolios using its reverse translation microbiome therapeutics capabilities to conduct research on various indications, including inflammatory and immune diseases, cancer, and metabolic diseases. 20 YEAR PERFORMANCE RESULTS |
MCRB Dividend History Detail MCRB Dividend News MCRB Competitors News |
Year |
Declaration Date |
Ex-Dividend Date |
Record Date |
Payable Date |
Dividend $ Amount |
Total: |
0.0000 |